BELITE BIO INC ADR
NASDAQ: BLTE (Belite Bio, Inc)
Kemas kini terakhir: 10 jam lalu187.86
9.53 (5.34%)
| Penutupan Terdahulu | 178.33 |
| Buka | 186.96 |
| Jumlah Dagangan | 363,818 |
| Purata Dagangan (3B) | 245,633 |
| Modal Pasaran | 7,047,498,752 |
| Harga / Pendapatan (P/E Ke hadapan) | 232.56 |
| Harga / Buku (P/B) | 24.96 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -1.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.37% |
| Nisbah Semasa (MRQ) | 25.98 |
| Aliran Tunai Operasi (OCF TTM) | -29.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.42 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Belite Bio, Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.93% |
| % Dimiliki oleh Institusi | 0.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ra Capital Management, L.P. | 30 Sep 2025 | 875,000 |
| Rtw Investments, Lp | 30 Sep 2025 | 312,500 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 312,500 |
| Soleus Capital Management, L.P. | 30 Sep 2025 | 210,000 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 195,312 |
| Marshall Wace, Llp | 30 Sep 2025 | 187,500 |
| Western Standard Llc | 31 Dec 2025 | 60,026 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 195.00 (B of A Securities, 3.80%) | Beli |
| Median | 191.00 (1.67%) | |
| Rendah | 154.00 (Cantor Fitzgerald, -18.02%) | Beli |
| Purata | 183.80 (-2.16%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 155.03 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 Jan 2026 | 185.00 (-1.52%) | Beli | 165.64 |
| 01 Dec 2025 | 185.00 (-1.52%) | Beli | 154.02 | |
| B of A Securities | 26 Jan 2026 | 195.00 (3.80%) | Beli | 162.47 |
| Morgan Stanley | 06 Jan 2026 | 191.00 (1.67%) | Beli | 160.18 |
| Mizuho | 02 Dec 2025 | 194.00 (3.27%) | Beli | 150.84 |
| 20 Nov 2025 | 105.00 (-44.11%) | Pegang | 109.18 | |
| Cantor Fitzgerald | 24 Nov 2025 | 154.00 (-18.02%) | Beli | 136.00 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |